Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Operating Expenses (2016 - 2026)

Intellia Therapeutics has reported Operating Expenses over the past 12 years, most recently at $115.6 million for Q1 2026.

  • Quarterly Operating Expenses fell 15.9% to $115.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $486.8 million through Mar 2026, down 17.02% year-over-year, with the annual reading at $508.7 million for FY2025, 14.1% down from the prior year.
  • Operating Expenses was $115.6 million for Q1 2026 at Intellia Therapeutics, down from $121.7 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $155.5 million in Q1 2022 and troughed at $112.3 million in Q2 2022.
  • The 5-year median for Operating Expenses is $137.4 million (2025), against an average of $134.0 million.
  • Year-over-year, Operating Expenses soared 194.11% in 2022 and then dropped 19.89% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $123.7 million in 2022, then grew by 11.58% to $138.0 million in 2023, then grew by 8.22% to $149.3 million in 2024, then fell by 18.48% to $121.7 million in 2025, then fell by 5.05% to $115.6 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Operating Expenses are $115.6 million (Q1 2026), $121.7 million (Q4 2025), and $125.3 million (Q3 2025).